Paradigm BiopharmaceuticalsASX:PAR 27 Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 840 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 99.88% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Paradigm Biopharmaceuticals's Revenue for the
six
months ended in Dec. 2025 was A$0.03 Mil. Paradigm Biopharmaceuticals's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$6.31 Mil.
Hence, Paradigm Biopharmaceuticals's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.00.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Paradigm Biopharmaceuticals Receivables Turnover Related Terms
Paradigm Biopharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PAR vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paradigm Biopharmaceuticals (ASX:PAR) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #839 out of 840 companies in the Biotechnology industry, placing it in the top 99.9%.
Is Paradigm Biopharmaceuticals' Receivables Turnover too high?
Paradigm Biopharmaceuticals' current Receivables Turnover is 0.00. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #839 out of 840 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #839 out of 840 companies for Receivables Turnover. This places Paradigm Biopharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score
Get the complete analysis for ASX:PAR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PAR has been successfully added to your 
